Later, based on the FLAURA 3 trial, the first-line application of osimertinib in EGFR mutant NSCLC patients resulted in longer progression-free survival (PFS) and longer overall survival (OS) than the first-line application of other EGFR-TKIs [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.